|
Living Medical Textbook From Projects In Knowledge |
|
| Chapter 1 Multiple Sclerosis Basics Last Reviewed: May 24, 2010 |
||
| Chapter 2 MRI and New Imaging Technologies in Multiple Sclerosis Last Reviewed: May 24, 2010 |
||
| Chapter 3 Currently Available Treatments for Multiple Sclerosis Last Reviewed: May 24, 2010 |
||
| Chapter 4 Small-Molecule Treatments In Development for Multiple Sclerosis Release date: May 25, 2010 |
||
| Chapter 5 Monoclonal Antibodies in Development for Multiple Sclerosis Release date: May 25, 2010 |
||
| Chapter 6 Managing Symptoms in Multiple Sclerosis Release date: July 14, 2010 |
||
|
||
|
|
||||||||||||||||
| Chapter 5 – Monoclonal Antibodies in Development for Multiple Sclerosis | ||||||||||||||||
|
||||||||||||||||
|
Activity Goal The goal of this CME/CE activity is to examine the pathophysiology, etiologic factors, classification, and diagnostic criteria of multiple sclerosis. |
||||||||||||||||
|
Target Audience This CME/CE activity is designed for neurologists, internal medicine specialists, family practice/primary care physicians, nurse specialists/nurse practitioners, physician assistants, and other health professionals who interact with and are involved in the management and treatment of patients with multiple sclerosis. |
||||||||||||||||
Learning Objective
|
||||||||||||||||
| top |
||||||||||||||||
|
CME Information: Physicians
Statement of Accreditation Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Projects In Knowledge designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. CE Information: Nurses Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227. This activity is approved for 1.08 nursing contact hour(s). DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, CBRN, or PIK endorsement of any commercial product or service. CE Information: Pharmacists  Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This chapter is worth up to 2.00 contact hours (0.2 CEUs). The ACPE Universal Activity Number assigned to this knowledge-based activity is 0052-0000-10-1110-H01-P. top |
||||||||||||||||
|
Disclosure Information The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR). Bruce A. Cohen, MD, has received honoraria and participated in speakers bureaus of Bayer Pharmaceuticals, Biogen Idec, EMD Serono, and Teva Neuroscience; has received consulting fees from Acorda Pharmaceuticals, Astellis, Bayer Pharmaceuticals, Biogen Idec, EMD Serono, Sanofi-Aventis, and Teva Neuroscience; and has ownership interest in Abbott Laboratories and CVS-Caremark. Clyde E. Markowitz, MD, Clyde E. Markowitz, MD, has received honoraria from Bayer, Biogen Idec, and Teva Neuroscience; is a consultant for Bayer, Genentech Inc, Biogen Idec, BioMS Medical, Eli Lilly and Company, EMD Serono, Novartis Pharmaceuticals Corporation and Teva Neuroscience. Lauren A. Cerruto has no significant relationships to report. Drug Disclosure Statement: This activity includes a discussion of the following therapies: alemtuzumab, daclizumab, ocrelizumab, ofatumumab, and rituximab, all of which are investigational or off-label in the treatment of MS. Peer Reviewer has disclosed no significant relationships. Projects In Knowledge’s staff members have no significant relationships to disclose. top |
||||||||||||||||
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process. The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge. This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|
||||||||||||||||
|
||||||||||||||||
|
|
|
These independent CME/CE activities are supported by an educational grant from Teva Neuroscience. |
|
|
Release Date: May 25, 2010. Termination Date: May 25, 2011. |
|
Estimated time for completion of this activity: CME: 2.0 hours CE: 1.08 hours CPE: 2.0 hours |
|
CME/CE Instructions To obtain CME/CE credit for this activity:
There is no fee for this activity. |
|
